VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 9, 2004--Active Pass announces the promotion of Dr. David MacDonald to the position of President & Chief Operating Officer. Concomitant with the appointment, Dr. MacDonald joins the Company's Board of Directors. Commenting on the appointment, Chief Executive Officer Dr. Peter B. Reiner stated, "It is a rare privilege to have someone of David's talents within the organization. His contributions to the business have been exemplary, and we are delighted to have him take on these additional responsibilities as the Company continues its transition from discovery to development."
David MacDonald, Ph.D. has over 15 years of experience at pharmaceutical and biotechnology firms, including a wide range of critical activities within the drug discovery and development process. Dr. MacDonald joined Active Pass in September 2001 as Vice President, Research and Development. Previously, he was General Manager of Biovail Contract Research, as well as having held positions of increasing responsibility at Syntex and Hemosol. Dr. MacDonald obtained his Ph.D. in Chemistry from the University of Alberta, where his research was focused on enzymology and enzyme kinetics.
About Active Pass
Active Pass is a privately held biotechnology company developing drugs that target ABC transporters, a valuable class of targets for diseases with substantial markets. Our gene-family approach to drug discovery enables us to profile compounds for potency, specificity and bioavailability, identifying those compounds most likely to survive the rigors of drug development. Moreover, our balanced portfolio of therapeutic programs, including secretory diarrhea, age-related macular degeneration, and lipid disorders, provides multiple opportunities for success.
Active Pass Pharmaceuticals, Vancouver
Peter B. Reiner, 604-879-2775